Arcturus Therapeutics
ARCT
124 hedge funds and large institutions have $558M invested in Arcturus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
66% more capital inflows, than outflows
Capital inflows: $44.8M | Capital outflows: $27M
19% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 36
12% more funds holding
Funds holding: 111 → 124 (+13)
3.49% more ownership
Funds ownership: 84.32% → 87.8% (+3.5%)
6% less call options, than puts
Call options by funds: $5.38M | Put options by funds: $5.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$5.61M |
| 3 |
Prosight Management
Dallas,
Texas
|
+$4.58M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.43M |
| 5 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$16.1M |
| 2 |
BlackRock
New York
|
-$1.59M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.47M |
| 4 |
Pura Vida Investments
New York
|
-$848K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$788K |
ARCT Hedge Fund Activity: Q1 2023 in Review
124 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2023, worth a combined $558M — up 47% from $379M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ARCT positions and 12 closed out — a net gain of 14 holders — while 43 added to existing stakes and 36 trimmed.
The largest buyer was Federated Hermes, adding an estimated $9.7M. The largest seller was Balyasny Asset Management, cutting an estimated $16.1M.
- 124 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2023, up from 111 in Q4 2022.
- Funds reported $558M of Arcturus Therapeutics stock for Q1 2023, up 47% quarter-over-quarter.
- 26 funds opened new Arcturus Therapeutics positions in Q1 2023 and 12 closed out, a net change of +14 holders.
- The largest Arcturus Therapeutics buyer in Q1 2023 was Federated Hermes, an estimated $9.7M added.
- The largest Arcturus Therapeutics seller in Q1 2023 was Balyasny Asset Management, an estimated $16.1M sold.
Based on aggregated 13F filings for Q1 2023.